Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 19, 2025.

The founder of the Stuttering Treatment and Research Society (STARS) discussed the unmet needs in stuttering care, current management strategies, and the mission of STARS to drive education, collaboration, and treatment development.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Michael Okun, MD. [LISTEN TIME: 14 minutes]

The founder of the Stuttering Treatment and Research Society (STARS) detailed current therapeutic strategies for stuttering, the role of dopamine pathways, and the pressing need for FDA-approved options. [WATCH TIME: 4 minutes]

SKY-0515 shows promising results in reducing mutant huntingtin protein in Huntington disease patients, paving the way for transformative treatment options.

At the 2025 STARS Research & Education Conference, the assistant professor of neurobiology and behavior at Stony Brook University discussed the current understanding of stuttering. [WATCH TIME: 5 minutes]

The CEO and cofounder of LSVT Global talked about how evidence-based therapies like LSVT LOUD and LSVT BIG can improve speech and movement in patients with Parkinson disease. [WATCH TIME: 5 minutes]

A recent study demonstrated that distinct aquaporin-4 changes in neuronal and glial synucleinopathies reflect different pathomechanisms and may warrant further investigation.

The vice chair of neurology at West Virginia University outlined key challenges in academic neurology and reflected on the evolving responsibilities of vice chairs in supporting departmental growth and leadership. [WATCH TIME: 3 minutes]

Movement disorder specialists from the Women Neurologists Group discussed supporting women in neurology through mentorship, innovation, and community connections. [WATCH TIME: 5 minutes]

Movement disorder specialists reflected on a decade of community, research, and career support in-person and online for members of the Women Neurologists Group. [WATCH TIME: 7 minutes]

Panelists discuss the growing role of continuous infusion therapies in managing advanced Parkinson disease, highlighting their effectiveness in reducing motor fluctuations and dyskinesia, improving quality of life, and supporting individualized, long-term treatment strategies amid ongoing advancements in drug delivery and patient selection.

Movement disorder specialists talked about how the 4th Annual Women in Neurology Conference will offer educational updates, career development, and networking opportunities for women across neurology. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Movement disorder specialists reflected on the community’s growth over the past decade in the Women Neurologists Group and shared program highlights of the group’s upcoming conference. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 12, 2025.

The director of the Neuroethics Program at Cleveland Clinic discussed ethics training, shared decision-making, and safeguards in guiding patients, families, and clinicians through complex clinical research decisions. [WATCH TIME: 3 minutes]

Tamara Kaplan, MD, vice chair of education for the department of neurology at Mass General Brigham, shares insights on evolving neurology education, highlighting her framework for supporting clinician educators and the growing recognition of education as a career path.

Teva's emrusolmin receives FDA fast track designation as a potential breakthrough treatment for multiple system atrophy, targeting neurodegeneration.

Catch up on any of the neurology news headlines you may have missed in August 2025, compiled into 1 place by the NeurologyLive® team.

A recent trial shows that 3 infusions of stem cells significantly enhance motor function in Parkinson patients, highlighting the need for further research.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.

Panelist discusses how distinguishing between dyskinesia (choreiform, dance-like movements) and tremor in Parkinson disease is crucial for treatment decisions, as modern therapeutic options including extended-release amantadine, continuous subcutaneous delivery systems, and advanced formulations can now effectively manage both motor fluctuations and troublesome dyskinesias simultaneously.

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.